DADC
FATE icon

D.A. Davidson & Co’s Fate Therapeutics FATE Stock Holding History

D.A. Davidson & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-720
Closed -$3K – 2383
2017
Q1 		$3K Hold
720
– – ﹤0.01% 2234
2016
Q4 		$1K Hold
720
– – ﹤0.01% 2394
2016
Q3 		$2K Hold
720
– – ﹤0.01% 2295
2016
Q2 		$1K Hold
720
– – ﹤0.01% 2283
2016
Q1 		$1K Hold
720
– – ﹤0.01% 2199
2015
Q4 		$2K Hold
720
– – ﹤0.01% 2128
2015
Q3 		$3K Hold
720
– – ﹤0.01% 2061
2015
Q2 		$4K Buy
+720
New +$4.31K ﹤0.01% 2032

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

D.A. Davidson & Co's FATE Position: Q2 2017 in Review

D.A. Davidson & Co sold out of Fate Therapeutics (FATE) in Q2 2017, closing a stake of 720 shares — an estimated $3K sold.

D.A. Davidson & Co first reported a position in FATE in Q2 2015 and held it in 8 quarters. The position peaked at $4K in Q2 2015. 60 funds tracked by Wall St. Rank hold FATE as of Q2 2017.

  • D.A. Davidson & Co reported no remaining Fate Therapeutics position as of Q2 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 720 Fate Therapeutics shares in Q2 2017, an estimated $3K.
  • D.A. Davidson & Co first reported a position in Fate Therapeutics in Q2 2015 and held it in 8 quarters.
  • D.A. Davidson & Co's Fate Therapeutics position peaked at $4K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2017.

Based on D.A. Davidson & Co's 13F filing for Q2 2017, filed 11 Aug 2017.